DCB Strengthens Drug Resilience, Focuses on ADC and Nucleic Acid Drugs
NQ Score
55/100
N1 Content Completeness
10
AI Summary (NQ-processed)
Tu Hsin-che, Chairman of the Development Center for Biotechnology (DCB), stated on the 28th that Taiwan must build autonomous drug supply capabilities to counter global supply chain uncertainties. The DCB will focus on high-end biologics, ADC, nucleic acid drugs, and green manufacturing processes to strengthen domestic supply resilience and help build a 'Biotech Silicon Valley' in Taiwan.
AI Analysis
Frequently Asked Questions
- Q: What is the strategic goal of DCB?
- A: To build a self-reliant drug supply chain and establish Taiwan as a 'Biotech Silicon Valley' by focusing on high-end biologics.